Radium-223

Radium-223 (Xofigo®) is a radiopharmaceutical chemically similar to calcium that is used to treat castration-resistant prostate cancer in patients with painful bone metastases. Because of its calcium-like chemical properties, radium-223 is absorbed in areas where bone is actively growing and healing, in place of calcium. Treatment with radium-223 both prolongs survival and improves quality of life, prolonging time to potential complications of advanced prostate cancer (such as pain, bone fractures, or spinal cord compression). Talk with your doctor about whether you should also receive a bone health agent when you are starting treatment with radium-223.

Last Reviewed: 12/2023